Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug863 | Cell therapy protocol 1 Wiki | 1.00 |
| drug864 | Cell therapy protocol 2 Wiki | 1.00 |
| drug2916 | Placebo Wiki | 0.04 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D012127 | Respiratory Distress Syndrome, Newborn NIH | 0.08 |
| D055371 | Acute Lung Injury NIH | 0.08 |
| D012128 | Respiratory Distress Syndrome, Adult NIH | 0.07 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
This is a phase III clinical trial to assess efficacy and safety of the Adsorbed COVID-19 (inactivated) vaccine manufactured by Sinovac in health care professionals
Description: Number of virologically-confirmed symptomatic COVID-19 two weeks after second dose of vaccine
Measure: Incidence of COVID-19 cases after two-doses immunization schedule Time: Two weeks after second dose up to one year after first doseDescription: Frequency of adverse reaction in the seven days following each immunization per age group
Measure: Frequency of adverse events up to seven days after immunization Time: Seven days after each immunizationDescription: Number of virologically-confirmed symptomatic COVID-19 two weeks after second dose of vaccine according to previous exposure to SARS-CoV-2
Measure: Incidence of COVID-19 cases after two-doses immunization schedule according to previous exposure Time: Two weeks after first dose up to one year after first doseDescription: Number of virologically-confirmed symptomatic COVID-19 two weeks after first dose of vaccine, regardless the vaccination schedule was completed
Measure: Incidence of COVID-19 cases after 14-days of first immunization Time: Two weeks after last dose uup to one year after first doseDescription: Number of virologically-confirmed and or serologically-confirmed SARS-CoV-2 infections two weeks after first dose of vaccine
Measure: Combined incidence of SARS-CoV-2 infection Time: Two weeks after second dose up to one year after first doseDescription: Number of virologically-confirmed severe COVID-19 two weeks after second dose of vaccine
Measure: Incidence of severe COVID-19 cases after two-doses immunization schedule Time: Two weeks after second dose up to one year after first doseDescription: Frequency of adverse reaction in the 28 days following each immunization per age group
Measure: Frequency of adverse events up to 28 days after immunization Time: 28 days after each immunizationDescription: Frequency of virologically-confirmed severe COVID-19 cases after receiving, at least, one dose of the vaccine
Measure: Frequency of severe COVID-19 cases Time: From first vaccination up to one year after first doseDescription: Frequency of adverse events of special interest after receiving, at least, one dose of the vaccine
Measure: Frequency of adverse events of special interest after immunization Time: From first vaccination up to one year after first doseDescription: Number of seroconversion responses to SARS-CoV-2 in the second week after each vaccination per age group in a subset of participants
Measure: Seroconversion rate Time: Two weeks after each vaccinationDescription: Number of cell-mediated immune response against SARS-CoV-2 in the week two and four after the second vaccination per age group in a subset of participants
Measure: Cell-mediated immune profile Time: Two and four weeks afer each vaccinationDescription: Number of seropositive responses to SARS-CoV-2 in the second week after each vaccination per age group in a subset of participants
Measure: Seropositivity rate Time: Two weeks after second vaccinationAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports